drugset / Trial / NCT00021021
RPI.4610 in Treating Patients With Metastatic Kidney Cancer
Treatment
Summary
RATIONALE: RPI.4610 may stop the growth of metastatic kidney cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of RPI.4610 in treating patients who have metastatic kidney cancer.
Timeline
- Start
- 2001-09
- Primary completion
- —
- Completion
- 2004-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RPI.4610 | Oligonucleotide (other) | — | Subcutaneous |